Celltrion’s Remsima challenges to Truxima’s KRW 8 trillion market
On the 19th(local time), Celltrion announced it received ‘recommendation of approval’ for every indication of the world’s first hematological malignancy anticancer biosimilar Truxima(generic name: rituximab, project name: CT-P10) from Committee for Medicinal Products for Human Use(CHMP), an affil...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
